The expression of cancer-testis antigen in ovarian cancer and the development of immunotherapy

Jianhang Zhao; Zhaoxu Xu; Yan Liu; Xiaobin Wang; Xinli Liu; Yanan Gao; Ying Jin

The expression of cancer-testis antigen in ovarian cancer and the development of immunotherapy

Am J Cancer Res. 2022 Feb 15;12(2):681-694. eCollection 2022.

Authors

Jianhang Zhao¹, Zhaoxu Xu¹, Yan Liu², Xiaobin Wang³, Xinli Liu⁴, Yanan Gao¹, Ying Jin²

Affiliations

¹ Department of Pharmacology, School of Pharmacy, China Medical University Shenyang, Liaoning, China.
² Liaoning Research Institute of Family Planning (Reproductive Hospital Affiliated to China Medical University), Key Laboratory of Reproductive Health and Genetic Medicine, National Health Commission of China Shenyang, Liaoning, China.
³ Center of Reproductive Medicine, Shengjing Hospital of China Medical University Shenyang, Liaoning, China.
⁴ Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University Shenyang, Liaoning, China.

PMID: 35261795
PMCID: PMC8899981

Abstract

Ovarian cancer is a relatively common tumor in women with the highest mortality among female reproductive system tumors. The lack of apparent early symptoms and effective screening strategies often leads to ovarian cancer being diagnosed at an advanced stage. Immunotherapy relying on tumor-associated antigens might improve the treatment of ovarian cancer. Cancer-testis antigens (CTAs) are ideal tumor-associated antigens, and MAGE-A, NY-ESO-1, CT45, and Sp17 are classic CTAs highly expressed in ovarian cancer. Here, we review the research on CTAs in ovarian cancer, including prognostic value and advances in immunotherapy, all of which are essential for developing a theoretical basis for targeted therapy strategies.

Keywords: Cancer-testis antigen; MAGE-A/NY-ESO-1/CT45/Sp17; immunotherapy; ovarian cancer.

Publication types

Review